Literature DB >> 23337772

Glucagon and GLP-1 inhibit food intake and increase c-fos expression in similar appetite regulating centres in the brainstem and amygdala.

J A Parker1, K A McCullough, B C T Field, J S Minnion, N M Martin, M A Ghatei, S R Bloom.   

Abstract

BACKGROUND: Glucagon and glucagon-like peptide-1 (GLP-1) are evolutionarily related anorectic hormones. Glucagon also increases energy expenditure. The combination of glucagon and GLP-1 could cause weight loss through a simultaneous reduction in food intake and increased energy expenditure. However, the effect of combined administration of glucagon and GLP-1 on food intake and neuronal activation has not previously been studied. Furthermore, the effect of glucagon on neuronal activation in appetite regulating centres has not been assessed. Characterisation of the effects of glucagon when administered singly and in combination with GLP-1 on neuronal activation will be important for determining the mechanism of action of related potential antiobesity therapies.
OBJECTIVES: To investigate the effects of peripherally administered GLP-1 and glucagon on food intake, neuronal activation and blood glucose in mice when administered individually and in combination.
METHODOLOGY: Food intake, blood glucose and c-fos expression in the hypothalamus, amygdala and brainstem were measured in response to GLP-1 and glucagon, alone and in combination.
RESULTS: Peripherally administered GLP-1 and glucagon decreased food intake and increased c-fos expression in the brainstem and amygdala. Doses of GLP-1 and glucagon that individually did not significantly affect feeding, in combination were anorectic and stimulated neuronal activation in the area postrema (AP) and central nucleus of the amygdala. Combined administration of GLP-1 and glucagon prevented the acute hyperglycemic effect of glucagon alone.
CONCLUSION: Anorectic doses of glucagon and GLP-1 induced similar patterns of c-fos expression. Combined administration of low dose GLP-1 and glucagon inhibited food intake and induced c-fos expression in the AP and amygdala. The combination of both hormones may offer the opportunity to utilise the beneficial effects of reduced food intake and increased energy expenditure, and may therefore be a potential treatment for obesity.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23337772     DOI: 10.1038/ijo.2012.227

Source DB:  PubMed          Journal:  Int J Obes (Lond)        ISSN: 0307-0565            Impact factor:   5.095


  32 in total

1.  c-Fos induction by gut hormones and extracellular ATP in osteoblastic-like cell lines.

Authors:  Elda Leonor Pacheco-Pantoja; Jane P Dillon; Peter J M Wilson; William D Fraser; James A Gallagher
Journal:  Purinergic Signal       Date:  2016-07-20       Impact factor: 3.765

Review 2.  Glucagon-like peptide 1 interacts with ghrelin and leptin to regulate glucose metabolism and food intake through vagal afferent neuron signaling.

Authors:  Charlotte C Ronveaux; Daniel Tomé; Helen E Raybould
Journal:  J Nutr       Date:  2015-02-04       Impact factor: 4.798

3.  The importance of GLP-1 and PYY in resistant starch's effect on body fat in mice.

Authors:  June Zhou; Roy J Martin; Anne M Raggio; Li Shen; Kathleen McCutcheon; Michael J Keenan
Journal:  Mol Nutr Food Res       Date:  2015-03-02       Impact factor: 5.914

Review 4.  Emerging combinatorial hormone therapies for the treatment of obesity and T2DM.

Authors:  Sharon A Sadry; Daniel J Drucker
Journal:  Nat Rev Endocrinol       Date:  2013-03-12       Impact factor: 43.330

Review 5.  Glucagon action in the brain.

Authors:  Mona A Abraham; Tony K T Lam
Journal:  Diabetologia       Date:  2016-04-26       Impact factor: 10.122

Review 6.  Potential Applications of Gliclazide in Treating Type 1 Diabetes Mellitus: Formulation with Bile Acids and Probiotics.

Authors:  Momir Mikov; Maja Đanić; Nebojša Pavlović; Bojan Stanimirov; Svetlana Goločorbin-Kon; Karmen Stankov; Hani Al-Salami
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2018-06       Impact factor: 2.441

Review 7.  Insulin and glucagon signaling in the central nervous system.

Authors:  Beatrice M Filippi; Mona A Abraham; Jessica T Y Yue; Tony K T Lam
Journal:  Rev Endocr Metab Disord       Date:  2013-12       Impact factor: 6.514

Review 8.  Future Pharmacotherapy for Obesity: New Anti-obesity Drugs on the Horizon.

Authors:  Gitanjali Srivastava; Caroline Apovian
Journal:  Curr Obes Rep       Date:  2018-06

9.  A novel glucagon-like peptide-1 (GLP-1)/glucagon hybrid peptide with triple-acting agonist activity at glucose-dependent insulinotropic polypeptide, GLP-1, and glucagon receptors and therapeutic potential in high fat-fed mice.

Authors:  Victor A Gault; Vikas K Bhat; Nigel Irwin; Peter R Flatt
Journal:  J Biol Chem       Date:  2013-10-28       Impact factor: 5.157

10.  Semaglutide lowers body weight in rodents via distributed neural pathways.

Authors:  Sanaz Gabery; Casper G Salinas; Sarah J Paulsen; Jonas Ahnfelt-Rønne; Tomas Alanentalo; Arian F Baquero; Stephen T Buckley; Erzsébet Farkas; Csaba Fekete; Klaus S Frederiksen; Hans Christian C Helms; Jacob F Jeppesen; Linu M John; Charles Pyke; Jane Nøhr; Tess T Lu; Joseph Polex-Wolf; Vincent Prevot; Kirsten Raun; Lotte Simonsen; Gao Sun; Anett Szilvásy-Szabó; Hanni Willenbrock; Anna Secher; Lotte Bjerre Knudsen; Wouter Frederik Johan Hogendorf
Journal:  JCI Insight       Date:  2020-03-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.